Seguridad de la terapia de interferón alfa 2b recombinante más ribavirina en la hepatitis crónica C

Sánchez Rodríguez, Yoan Antonio; Arús Soler, Enrique; López Saura, Pedro; Nodarse Cuní, Hugo.
Rev. cuba. farm ; 45(1): 34-43, ene.-mar. 2011.
Artículo en Español | LILACS | ID: lil-584573

Documentos relacionados

  1. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
  2. Pharmacological interventions for acute hepatitis C infection.
  3. [Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C].
  4. The Severity of Depressive Symptoms as an Independent Predictor of Sustained Virological Response During Treatment of Hepatitis C With Pegylated Interferon-α2a and Oral Ribavirin.
  5. Pretransplant ribavirin and interferon-α therapy for rhinovirus interstitial pneumonia in a RAG1-deficient infant.
  6. Histomorphometric Findings May Help Predicting Response in Patients with Chronic Liver Disease.
  7. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.
  8. Safety assessment of chronic hepatitis C treatment using h-FABP and 24-hour ECG Holter monitoring.
  9. [Clinical features of antiviral therapy-induced thyroid disease in patients with chronic hepatitis C].
  10. Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease.